Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression

More than eleven million U.S. Veterans are at least 65 years of age, an age group of which almost 20% suffers from clinically significant depressive symptoms. Available pharmacological treatments are suboptimal for patients, including veterans, with late-life depression. Ketamine has emerged as a po...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Brien, Brittany, Green, Charles E., Al-Jurdi, Rayan, Chang, Lee, Lijffijt, Marijn, Iqbal, Sidra, Iqbal, Tabish, Swann, Alan C., Mathew, Sanjay J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727003/
https://www.ncbi.nlm.nih.gov/pubmed/31508531
http://dx.doi.org/10.1016/j.conctc.2019.100432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727003/
https://www.ncbi.nlm.nih.gov/pubmed/31508531
http://dx.doi.org/10.1016/j.conctc.2019.100432

Ejemplares similares